Importance of Lifetime Sexual History on the Prevalence of Genital Human Papillomavirus (HPV) Among Unvaccinated Adults in the National Health and Nutrition Examination Surveys: Implications for Adult HPV Vaccination.
HPV prevalence
HPV vaccination
NHANES
genital HPV
sexual behavior
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
04 05 2021
04 05 2021
Historique:
received:
13
04
2020
pubmed:
28
7
2020
medline:
21
5
2021
entrez:
26
7
2020
Statut:
ppublish
Résumé
Although the United States Food and Drug Administration recently approved the human papillomavirus (HPV) vaccine for individuals aged 27-45 years, the Centers for Disease Control and Prevention did not change its guidelines for routine HPV vaccination. Since recommendations for adult vaccination emphasize shared clinical decision-making based on risk of new infections, we examined the relationship between HPV prevalence and sexual behavior. This study was conducted among 5093 HPV-unvaccinated, sexually experienced adults aged 18-59 years in the National Health and Nutrition Examination Surveys (2013-2016). For each sex and age group, adjusted prevalences of 9-valent vaccine-specific, high-risk, and any HPV infection were estimated by number of lifetime sexual partners (LTSPs) using logistic regression. An analysis restricted to persons who did not have a new sexual partner in the past year (ie, removing those at highest risk of newly acquired HPV) was also conducted. In each age group, genital HPV prevalence was higher among persons with >5 LTSPs compared with 1-5 LTSPs in both males and females. There were only slight reductions in HPV prevalence after removing participants who reported a new sexual partner in the past year. For example, among females aged 27-45 years with >5 LTSPs, the adjusted prevalence of 9-valent vaccine-type HPV infection was 13.4% (95% confidence interval [CI], 9.9%-17.0%) in the full population compared to 12.1% (95% CI, 8.8%-15.4%) among those with no new sexual partners. Prevalent HPV infection was primarily reflective of cumulative exposures over time (higher LTSPs). New exposures had limited impact, emphasizing the need to consider sexual history in the decision-making process for adult HPV vaccination.
Sections du résumé
BACKGROUND
Although the United States Food and Drug Administration recently approved the human papillomavirus (HPV) vaccine for individuals aged 27-45 years, the Centers for Disease Control and Prevention did not change its guidelines for routine HPV vaccination. Since recommendations for adult vaccination emphasize shared clinical decision-making based on risk of new infections, we examined the relationship between HPV prevalence and sexual behavior.
METHODS
This study was conducted among 5093 HPV-unvaccinated, sexually experienced adults aged 18-59 years in the National Health and Nutrition Examination Surveys (2013-2016). For each sex and age group, adjusted prevalences of 9-valent vaccine-specific, high-risk, and any HPV infection were estimated by number of lifetime sexual partners (LTSPs) using logistic regression. An analysis restricted to persons who did not have a new sexual partner in the past year (ie, removing those at highest risk of newly acquired HPV) was also conducted.
RESULTS
In each age group, genital HPV prevalence was higher among persons with >5 LTSPs compared with 1-5 LTSPs in both males and females. There were only slight reductions in HPV prevalence after removing participants who reported a new sexual partner in the past year. For example, among females aged 27-45 years with >5 LTSPs, the adjusted prevalence of 9-valent vaccine-type HPV infection was 13.4% (95% confidence interval [CI], 9.9%-17.0%) in the full population compared to 12.1% (95% CI, 8.8%-15.4%) among those with no new sexual partners.
CONCLUSIONS
Prevalent HPV infection was primarily reflective of cumulative exposures over time (higher LTSPs). New exposures had limited impact, emphasizing the need to consider sexual history in the decision-making process for adult HPV vaccination.
Identifiants
pubmed: 32710745
pii: 5876408
doi: 10.1093/cid/ciaa1050
pmc: PMC8096262
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e272-e279Subventions
Organisme : NCI NIH HHS
ID : P50 CA098252
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128779
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI102623
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120938
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408
pubmed: 27977643
J Natl Cancer Inst. 2005 Apr 20;97(8):577-86
pubmed: 15840880
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):200-8
pubmed: 24130223
BMJ. 2014 Mar 04;348:g1458
pubmed: 24594809
Diagn Mol Pathol. 2011 Jun;20(2):101-4
pubmed: 21532491
Stata J. 2019 Sep;19(3):510-522
pubmed: 31814807
Clin Infect Dis. 2017 Sep 15;65(6):893-899
pubmed: 28531261
J Virol. 2014 Jan;88(1):710-6
pubmed: 24173230
Nat Rev Clin Oncol. 2016 Feb;13(2):119-32
pubmed: 26323382
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13573-13578
pubmed: 29208707
Vaccine. 2018 Oct 15;36(43):6373-6378
pubmed: 30249423
Hum Vaccin Immunother. 2018;14(12):3010-3018
pubmed: 30024823
J Infect Dis. 2013 Nov 1;208(9):1404-15
pubmed: 23885113
Obstet Gynecol. 2010 Jun;115(6):1150-1158
pubmed: 20502284
Viruses. 2017 Sep 21;9(10):
pubmed: 28934151
Gynecol Oncol. 2013 Aug;130(2):264-8
pubmed: 23623831
Int J Cancer. 2016 Nov 15;139(10):2201-12
pubmed: 27448488
Philos Trans R Soc Lond B Biol Sci. 2019 May 27;374(1773):20180297
pubmed: 30955488
Lancet Child Adolesc Health. 2018 Oct;2(10):707-714
pubmed: 30236379
Cancer Res. 2012 Dec 1;72(23):6183-90
pubmed: 23019223
J Infect Dis. 2017 Sep 1;216(5):604-611
pubmed: 28931221
Ann Intern Med. 2020 Jan 7;172(1):22-29
pubmed: 31816629
MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702
pubmed: 31415491
J Clin Invest. 2011 Dec;121(12):4593-9
pubmed: 22133884
Vital Health Stat 2. 2018 Jan;(177):1-26
pubmed: 29775431
Gynecol Oncol. 2018 Nov;151(2):229-234
pubmed: 30197061
Int J Cancer. 2016 Jun 15;138(12):2867-74
pubmed: 26856527
Biometrics. 1999 Jun;55(2):652-9
pubmed: 11318229
Vaccine. 2019 Aug 23;37(36):5460-5465
pubmed: 31331772